-
EMA starts evaluating Spikevax in young children
EMA starts evaluating Spikevax in young children
-
EMA starts evaluating Spikevax in young children
EMA starts evaluating Spikevax in young children
EMA starts evaluating an application to extend the use of Moderna’s COVID-19 vaccine, Spikevax, to children aged 6 to 11
-
Update on molnupiravir
Update on molnupiravir
-
Update on molnupiravir
Update on molnupiravir
EMA starts a review to support possible national decisions on early use of oral antiviral molnupiravir, ahead of authorisation
-
PRAC highlights November 2021
PRAC highlights November 2021
-
PRAC highlights November 2021
PRAC highlights November 2021
Outcomes from the November meeting: updates on the safety of COVID-19 vaccines and a medicine for blood cancers
-
EMA organises its 4th public meeting on COVID-19
EMA organises its 4th public meeting on COVID-19
-
EMA organises its 4th public meeting on COVID-19
EMA organises its 4th public meeting on COVID-19
The meeting will take place on 25 November 2021 and will update European citizens on the approval and safety monitoring of COVID-19 vaccines and therapeutics in the EU
